当前位置: X-MOL首页 › SCI期刊查询及投稿分析系统 › Pharmacological Research杂志
Pharmacological Research
基本信息
期刊名称 | Pharmacological Research PHARMACOL RES |
---|---|
期刊ISSN | 1043-6618 |
期刊官方网站 | https://www.sciencedirect.com/journal/pharmacological-research |
是否OA | No |
出版商 | Academic Press |
出版周期 | Monthly |
文章处理费 | 登录后查看 |
始发年份 | 1989 |
年文章数 | 329 |
影响因子 | 9.1(2023) scijournal影响因子 greensci影响因子 |
中科院SCI期刊分区
大类学科 | 小类学科 | Top | 综述 |
---|---|---|---|
医学2区 | PHARMACOLOGY & PHARMACY 药学1区 | 是 | 否 |
CiteScore
CiteScore排名 | CiteScore | SJR | SNIP | ||
---|---|---|---|---|---|
学科 | 排名 | 百分位 | 18.7 | 2.160 | 1.715 |
Pharmacology, Toxicology and Pharmaceutics Pharmacology |
9/313 | 97% |
补充信息
自引率 | 2.2% |
---|---|
H-index | 118 |
SCI收录状况 |
Science Citation Index Expanded |
官方审稿时间 | 登录后查看 |
网友分享审稿时间 | 数据统计中,敬请期待。 |
接受率 | 登录后查看 |
PubMed Central (PMC) | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1043-6618%5BISSN%5D |
投稿指南
期刊投稿网址 | https://www.editorialmanager.com/YPHRS |
---|---|
收稿范围 | Bridging across disciplines An IUPHAR-affiliated journal, International Union of Basic and Clinical Pharmacology Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. We provide a venue through which specialists across disciplines can rapidly exchange information in health sciences that pertains to modern pharmacological topics. The journal publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles. Invited and unsolicited review articles are welcome. Journal Sections Specific sections are dedicated to: The cardiovascular system: CV disease therapy; Signal transduction and receptor pharmacology in the CV system; Target organs; Clinical trials. Neuroscience, including psychopharmacology, and neuroendocrinology: Understanding of the central nervous system in physiological and pathological conditions; Neuropharmacological and molecular mechanisms of learning and memory; Therapeutic and diagnostic challenges for mental illness and neurodegerative diseases; System biology. Oncology: Targeted cancer therapy; Precision medicine and personalized therapy; Signal transduction studies, as related to drug action; Clinical trials. Immunology (clinical and basic): Immune and inflammatory mechanisms including target identification; Immunotherapy and immunotoxicology; Immunopathology; Vaccines and adjuvants; Treatment of infectious diseases. Redox regulators and biological gases in pathophysiology: Oxidative and nitrative stress and cell dysfunction; Redox regulation of signal transduction in various diseases; Pathophysiological roles of NO, CO and H2S; Interaction between oxidants and gaseous mediators in health and disease; Pharmacological modulators of oxidants, free radicals and gaseous transmitters. Renal Pathophysiology and Pharmacology: Acute and chronic kidney injury disease; Metabolic alkalosis and metabolic acidosis in renal disease; Renal excretion in electrolyte disorders; Diabetes insipidus, Diabetic nephropathy; Pathogenesis of glomerular disease; End stage renal disease; Prevention and treatment of nephrotic diseases. Pregnancy Related Pharmacology and Perinatal Therapeutics: Drug effects on the mother and foetus before and after birth; Placental barrier and its relationship with drugs (transportation metabolism and so on); Molecular signalling in placenta and identification of mechanisms beyond drug action in pregnancy; Adverse effects of drugs drug/combination in placenta; Drug repurposing/reprogramming for placenta-related disorders; Regulatory aspects beyond clinical research in pregnant mothers; Placenta remodelling in disease; In vivo models of the diseased placenta; The microbioma; Effects of the environment on pregnancy; Preventive vs therapeutic use of drugs. Pharmacogenomics, Pharmacogenetics and Precision Medicine: We are especially interested in GWAS studies and studies reporting pharmacogenetic data that are relevant in terms of safety and efficacy of drugs. They must provide insight into novel genomic or therapeutic associations that can help guide therapy selection or suggest new indications for established drugs. Studies can also provide details of exceptional responses in limited numbers of patients. We also publish n=1 studies of exceptional responses, provided they are backed up by compelling genomic or experimental data. Studies must include full clinical description of the case, along with details of the response and supporting molecular information. The molecular information should support the clinical observations and offer a definitive pharmacogenomic insight. Standard clinical sequencing assays (Foundation ONE, Genoptix etc) are only appropriate when the therapeutic or phenotypic response is novel. Ideally, the observational patient studies should be supported by lab based functional data. Bioactive molecules derived from medicinal plants or natural products: New, effective bioactive molecules; Drug target identification; Treatment mechanism; Mechanism investigation with -omics and computational technologies; Combinational therapy with natural products; Multi-targeting and network pharmacology; Herbal bioinformatics; Precision medicine of natural products; Evidenced-based research and clinical trials. Studies reporting on plant extracts in which the active principle(s) has not been defined do not fall into the scope of this journal. Exceptions can be made for papers addressing the mechanisms of actions or the clinical applications of standardized herbal preparations. Clinical studies on commercially-available nutraceuticals are also taken into consideration. Rare diseases and orphan drugs, and drug repositioning We also publish articles focusing on: Gastrointestinal and urogenital apparatuses when involving pharmacological issues; Pharmacology of tissue repair/regeneration; Pharmacology of aging; Nutraceuticals (if relevant to human disease); Pharmacoeconomy; Pharmacoepidemiology. We do not publish: Papers reporting pharmacological activities of novel compounds if no proper controls with known substances are performed; Bioequivalence studies or studies reporting only the pharmacokinetics profile of a compound; Descriptive pharmacovigilance studies; Single dose/concentration studies and those measuring only one endpoint. |
收录体裁 | Original articles Review articles and meta-analyses Opinion articles and Perspectives Letters to the Editor |
投稿指南 | https://www.sciencedirect.com/journal/pharmacological-research/publish/guide-for-authors |
投稿模板 | |
参考文献格式 | https://www.elsevier.com/journals/pharmacological-research/1043-6618/guide-for-authors |
编辑信息 |
|
我要分享 (欢迎您来完善期刊的资料,分享您的实际投稿经验)